Are there many treatment options for Osimertinib/Tagressa resistance?

Osimertinib/Tagrisso (Osimertinib) is a targeted drug used to treat EGFR mutation-positive non-small cell lung cancer. Although osimertinib has demonstrated significant efficacy in primary and outcome measures, particularly in the first-line setting, most patients develop resistance over time. When patients develop resistance to osimertinib, doctors usually consider other treatment options.

Mechanisms of resistance includeEGFR-dependent alterations, primarily the acquisition of the C797S mutation, which blocks drug binding; and EFGR-independent mechanisms, including MET and HER2 amplification, KRAS/BRAF/PIK3CA mutations, oncogenic fusions, and histological transformation. In order to guide the next step of treatment, readmission after disease progression is strongly recommended. Fourth-generation EGFR-TKIs are undergoing clinical research, and the results of clinical trials are awaited.

After resistance to osimertinib, doctors can also customize treatment plans based on the patient's individual conditions. Through genetic testing, doctors can understand the patient's tumor characteristics and select appropriate targeted drugs or other treatments. Alternative treatment options include other available targeted therapies, as well as combinations of chemotherapy with immunotherapy and anti-angiogenic therapies, or cytotoxic chemotherapy alone.

Different targeted drugs have different mechanisms of action and can overcome some resistance mechanisms. Chemotherapy remains a common option for patients who are resistant to osimertinib. For example, Cisplatin and Carboplatin are often combined with other drugs such as Etoposide or Pemetrexed. These combinations may have some efficacy in some patients. For patients who are resistant to osimertinib, participating in clinical trials is an important option. Clinical trials can provide new treatment strategies and drug options that can help improve patient prognosis and survival.